Happy holidays to those celebrating Passover or Easter this week and happy spring to all. As always, continue reading for another collection of the best of biotech and pharma commentary, analysis, and trends from around the web.
Sen. Wyden's Proposal Will Kill NIH-Pharma Collaboration
John LaMattina (Forbes)
A quick and brutally effective take-down of the ill-informed congressman
Conquering the complexities of biologics to get to biosimilars
Eric Palmer (FiercePharma)
Another in the seemingly endless drumbeat of stories about the troubles in biosimilar-ville
Do you think "biosimilars" will reduce healthcare expenditures? Think again
Henry Miller (Forbes)
And another.
Palifosamide: a predictable failure in soft tissue sarcoma?
Sally Church (Pharma Strategy Blog)
Quick reaction to the ZIOP, what it means for THLD, and more
Point of view: the writing on the wall
Henry Bourne (eLIFE)
A thorough piece on the structural problems in the grant-funded biomedical research world, along with ideas for improvement
Phil Needleman's Ten Commandments of Drug R&D
Bruce Booth (LifeSciVC)
John LaMattina (Forbes)
A quick and brutally effective take-down of the ill-informed congressman
Conquering the complexities of biologics to get to biosimilars
Eric Palmer (FiercePharma)
Another in the seemingly endless drumbeat of stories about the troubles in biosimilar-ville
Do you think "biosimilars" will reduce healthcare expenditures? Think again
Henry Miller (Forbes)
And another.
Palifosamide: a predictable failure in soft tissue sarcoma?
Sally Church (Pharma Strategy Blog)
Quick reaction to the ZIOP, what it means for THLD, and more
Point of view: the writing on the wall
Henry Bourne (eLIFE)
A thorough piece on the structural problems in the grant-funded biomedical research world, along with ideas for improvement
Phil Needleman's Ten Commandments of Drug R&D
Bruce Booth (LifeSciVC)
RSS Feed
